Suicidal behaviour and cognition: A systematic review with special focus on prefrontal deficits

BACKGROUND: Suicide is a major health concern worldwide, thus, identifying risk factors would enable a more comprehensive understanding and prevention of this behaviour. Neuropsychological alterations could lead to difficulties in interpreting and managing life events resulting in a higher risk of suicide. METHOD: A systematic literature search from 2000 to 2020 was performed in Medline (Pubmed), Web of Science, SciELO Citation Index, PsycInfo, PsycArticles and Cochrane Library databases regarding studies comparing cognition of attempters versus non-attempters that share same psychiatric diagnosis. RESULTS: 1.885 patients diagnosed with an Affective Disorder (n=1512) and Schizophrenia/ Schizoaffective Disorder (n=373) were included. In general comparison, attention was found to be clearly dysfunctional. Regarding diagnosis, patients with Schizophrenia and previous history of suicidal behaviour showed a poorer performance in executive function. Patients with current symptoms of an Affective Disorder and a previous history of suicidal attempt had poorer performance in attention and executive function. Similarly, euthymic affective patients with history of suicidal behaviour had worse decision-making, attention and executive function performance compared to euthymic non-attempters. LIMITATIONS: The number of papers included in this review is limited to the few studies using non-attempter clinically-matched control group and therefore results regarding diagnosis, symptomatology and time of the attempt are modest and contradictory. CONCLUSIONS: Patients who have attempted suicide have a poorer neuropsychological functioning than non-attempters with a similar psychiatric disorder in attention and executive function. These alterations increase vulnerability for suicide.This work was supported by Carlos III Health Research Institute[grant numbers PI14/02029, PI15/00793, PI15/00789, PI16/01164,PI17/01433 and PI18/01055 (co-financed by the European RegionalDevelopment Fund(FEDER/ERDF)/European Social Fund‘Investing inyour future’ and the Government of the Principality of Asturias PCTI-2018–2022 IDI/2018/235)], Foundation for Health Innovation andResearch (BIOEF); Bioaraba Research Institute; Networking Center forBiomedical Research in Mental Health (CIBERSAM), the BasqueGovernment [grant numbers 2015111024, 2017111104] and theUniversity of the Basque Country [grant number 321212ELBY]. Thepsychiatric research department in Araba University Hospital is sup-portedbytheStanleyResearchFoundation[grantnumber03-RC-003

The role of genetic variability in the GABRA6, 5-HTT and BDNF genes in anxiety-related traits

Objective:  The aims of this study were to test the individual association of the serotonin transporter gene (SLC6A4), the brain-derived neurotrophic factor gene (BDNF) and the GABAAα6 receptor subunit gene (GABRA6) with anxiety-related traits and to explore putative gene-gene interactions in a Spanish healthy sample. Method:  A sample of 937 individuals from the general population completed the Temperament and Character Inventory questionnaire to explore Harm Avoidance (HA) dimension; a subsample of 553 individuals also filled in the Big Five Questionnaire to explore the Neuroticism dimension. The whole sample was genotyped for the 5-HTTLPR polymorphism (SLC6A4 gene), the Val66Met polymorphism (BDNF gene) and the T1521C polymorphism (GABRA6 gene). Results:  Homozygous individuals for the T allele of the T1512C polymorphism presented slightly higher scores for HA than C allele carriers (F = 2.96, P = 0.019). In addition, there was a significant gene-gene interaction on HA between the 5-HTTLPR and Val66Met polymorphisms (F = 3.4, P = 0.009). Conclusion:  GABRA6 emerges as a candidate gene involved in the variability of HA. The effect of a significant gene-gene interaction between the SLC6A4 and BDNF genes on HA could explain part of the genetic basis underlying anxiety-related traits

Emotional intelligence: A comparison between patients after first episode mania and those suffering from chronic bipolar disorder type i

Deficits in emotional intelligence (EI) were detected in patients with Bipolar Disorder (BD), but little is known about whether these deficits are already present in patients after presenting a first episode mania (FEM). We sought (i) to compare EI in patients after a FEM, chronic BD and healthy controls (HC); (ii) to examine the effect exerted on EI by socio-demographic, clinical and neurocognitive variables in FEM patients. Methods: The Emotional Intelligence Quotient (EIQ) was calculated with the MayerSalovey-Caruso Intelligence Test (MSCEIT). Performance on MSCEIT was compared among the three groups using generalized linear models. In patients after a FEM, the influence of socio-demographic, clinical and neurocognitive variables on the EIQ was examined using a linear regression model. Results: 184 subjects were included (FEM n=48, euthymic chronic BD type I n=75, HC n=61). BD patients performed significantly worse than HC on the EIQ (Mean Difference MD=10.09, Standard Error SE=3.14, p=0.004) and on the Understanding emotions branch (MD=7.46, SE=2.53, p=0.010). FEM patients did not differ from HC and BD on other measures of MSCEIT. In patients after a FEM, EIQ was positively associated with female sex (β=-0.293, p=0.034) and verbal memory performance (β=0.374, p=0.008). FEM patients performed worse than HC but better than BD on few neurocognitive domains. Conclusions: Patients after a FEM showed preserved EI, while patients in later stages of BD presented lower EIQ, suggesting that impairments in EI might result from the burden of disease and neurocognitive decline, associated with the chronicity of the illness

Guía de práctica clínica para el tratamiento farmacológico y psicológico de los pacientes adultos con trastorno bipolar y un diagnóstico comórbido de trastorno por uso de sustancias

This review synthesizes the pharmacological and psychosocial interventions that have been conducted in comorbid bipolar disorder (BD) and substance use disorders (SUDs) while also providing clinical recommendations about which intervention elements are helpful for addressing substance use versus mood symptoms in patients with these co-occurring conditions. The best evidence from randomized controlled trials was used to evaluate treatment options. The strength of recommendations was described using the GRADE approach. Very few of the randomized trials performed so far have provided consistent evidence for the management of both mood symptoms and substance use in patients with a BD. No clinical trials are available for bipolar patients using cannabis. Some treatments have shown benefit for mood symptoms without benefits for alcohol or illicit substance use. Our results suggest that 1) we can (weakly) recommend the use of adjuvant valproate or naltrexone to improve symptoms of alcohol use disorder; 2) Lamotrigine add-on therapy seems to reduce cocaine-related symptoms and is therefore recommended (moderate strength); and 3) Varenicline is (weakly) recommended to improve nicotine abstinence. Integrated group therapy is the most-well validated and efficacious approach on substance use outcomes if substance use is targeted in an initial treatment phaseEsta revisión resume las intervenciones farmacológicos y psicosociales que se han realizado en trastorno bipolar (TB) y un diagnóstico comórbido de trastorno por uso de sustancias (TUS) y además proporciona recomendaciones clínicas respecto de cuáles elementos de intervención son útiles para hacer frente a los síntomas del uso de sustancias versus los síntomas de estado de ánimo en pacientes con estas afecciones concurrentes. Se utilizó la mejor evidencia de ensayos controlados aleatorizados para evaluar las opciones de tratamiento. La fuerza de las recomendaciones se describió mediante el enfoque GRADE. Muy pocos de los ensayos aleatorizados realizados hasta la fecha han proporcionado evidencia consistente para el manejo tanto de los síntomas de estado de ánimo como del uso de sustancias en pacientes con TB. No hay disponibilidad de ensayos clínicos para pacientes con TB que utilizan el cannabis. Algunos tratamientos han mostrado beneficios para los síntomas de estado de ánimo sin beneficios para el uso de alcohol o sustancias ilícitas. Nuestros resultados sugieren que 1) podemos (débilmente) recomendar el uso de ácido valproico o naltrexona adyuvante para aliviar los síntomas del trastorno por consumo de alcohol; 2) el tratamiento complementario con lamotrigina parece reducir los síntomas relacionados con la cocaína y, por tanto, es recomendable (fuerza moderada); y 3) la vareniclina es recomendable (débilmente) para mejorar la abstinencia de la nicotina. La terapia grupal integrada es el enfoque con más validación y eficacia sobre los resultados en el uso de sustancias cuando este uso es abordado durante la fase inicial de tratamientoS

El programa multicomponente de apoyo para el cese del tabaquismo (McSCSP) es efectivo en pacientes con trastorno mental grave sin diferencias de género.

High prevalence of smoking in people with severe mental disorders (SMD) contributes to their medical morbidity and reduced life expectancy. Despite the evidence of gender differences in smoking cessation, few studies have tested those differences among people with SMD. This is a non-randomized, open-label, prospective, 9-month follow-up multicentre trial to examine gender differences in the efficacy, safety and tolerability of a Multi-Component Smoking Cessation Support Programme (McSCSP). The results showed that there were no significant differences in short- (males 44.9% vs females 57.7%, chi-square = 1.112, p = 0.292) or long-term efficacy (week 24: males 40.8%, females 42.3%, chi-square = 0.016, p = 0.901; week 36: males 36.7%, females 38.5%, chi-square = 0.022, p = 0.883) between gender, neither controlled by diagnosis or treatment. Regarding safety and tolerability, there was significant increase in abdominal perimeter in males [from 105.98 (SD 13.28) to 108.52 (SD 14.01), t = -3.436, p = 0.002)], but not in females. However, there were no significant gender differences in adverse events (constipation, abnormal/vivid dreams, nausea/vomiting or skin rash/redness around patch site). In conclusion, we have demonstrated that is effective and safe to help either male or female patients with stabilized SMD to quit smoking. However, it might be a tendency in females to respond better to varenicline treatment in the short-term. Future research with larger samples is required to more clearly determine whether or not the there are differences, in addition to their reliability and robustness

The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxiety related traits

The aims of this study were to test the individual association of the 5-HTT, BDNF, and GABRA6 genes with anxiety-related traits and to explore putative GxG interactions in a healthy sample. Method: A sample of 937 individuals from the general population completed the TCI questionnaire; a subsample of 553 individuals also filled in a brief version of the NEO inventory. The whole sample was genotyped for the 5-HTTLPR polymorphism (5- HTT gene), the Val66Met polymorphism (BDNF gene) and the T1521C polymorphism (GABRA6 gene). Results: Individuals carrying the TTgenotype of the T1512C polymorphism presented slightly higher scores for Harm Avoidance ( HA ) than C allele carriers (F=2.96, p=0.051). In addition, there was a significant GxG interaction on HA between the 5-HTTLPR and Val66Met polymorphisms (F=3.4, p=0.009). Conclusion: GABRA6 emerges as a putative gene may be involved in the variability of HA. The effect of a significant GxG interaction between the 5-HTT and BDNF genes on HA could explain part of the genetic basis underlying anxiety-related traits

The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxiety related traits

The aims of this study were to test the individual association of the 5-HTT, BDNF, and GABRA6 genes with anxiety-related traits and to explore putative GxG interactions in a healthy sample. Method: A sample of 937 individuals from the general population completed the TCI questionnaire; a subsample of 553 individuals also filled in a brief version of the NEO inventory. The whole sample was genotyped for the 5-HTTLPR polymorphism (5- HTT gene), the Val66Met polymorphism (BDNF gene) and the T1521C polymorphism (GABRA6 gene). Results: Individuals carrying the TTgenotype of the T1512C polymorphism presented slightly higher scores for Harm Avoidance ( HA ) than C allele carriers (F=2.96, p=0.051). In addition, there was a significant GxG interaction on HA between the 5-HTTLPR and Val66Met polymorphisms (F=3.4, p=0.009). Conclusion: GABRA6 emerges as a putative gene may be involved in the variability of HA. The effect of a significant GxG interaction between the 5-HTT and BDNF genes on HA could explain part of the genetic basis underlying anxiety-related traits

Sex-dependent grades of haematopoietic modulation in patients with major depressive episodes are associated with suicide attempts

International audienceSuicide is the leading cause of non-natural death worldwide, and major depressive disorder (MDD) is the mood disorder with the highest prevalence among individuals with suicidal behaviour (SB). The role of inflammation and immunomodulation in mood disorders has raised interest in recent years, as inflammation biomarkers have been reported to be increased in mood disorder patients, suggesting a role of inflammation in their pathogenesis. The influence of inflammation on the haematopoietic production is well known; however, a comprehensive study of the haematopoietic production in patients with major depressive episodes (MDE) is lacking. We examined global haematopoietic parameters from complete blood counts (CBC) of patients with MDE, in search of prognostic patterns. MDE patients presented differences in several CBC parameters, differences that were clearly pronounced and/or significant in concurrence with suicide attempts (SA). Red and white blood cell lineage parameters were affected, suggesting general haematopoietic modulation or imbalance. We observed distinct haematological parameter changes in women versus men, with men presenting milder alterations than women. Interestingly, we found that the List of Threatening Experiences (LTE) score, but not the Childhood Trauma Questionnaire (CTQ), was associated with the haematopoietic alterations observed exclusively in women and, more importantly, served as a parameter to stratify female MDE patients based on concurrence or non-concurrence with SA. In conclusion, grades of haematopoietic modulation in MDE patients are associated with absence or presence of SA. Haematopoietic manifestations differ between men and women and, in the latter, are markedly influenced by late, and not early, traumatic events

Psicothema

Resumen tomado de la publicaciónEl presente estudio examinó las propiedades psicométricas del Addiction Severity Index-6 (ASI-6) en su versión traducida y adaptada al español. Se realizó un estudio multicéntrico, observacional y prospectivo donde participaron un total de 258 sujetos, siendo 217 pacientes (35 estables y 182 inestables) y 41 controles. Los resultados muestran que el ASI-6 presentó un buen comportamiento psicométrico. Los niveles de consistencia interna de las puntuaciones objetivas estandarizadas de las escalas del ASI-6 oscilaron entre 0,47 y 0,95. Por su parte, los valores de fiabilidad test-retest fueron aceptables, oscilando entre 0,36 y 1. El estudio de la estructura interna del ASI-6 informó que todas las escalas, considerándolas de forma independiente, se ajustaron a una solución esencialmente unidimensional. En cuanto a la obtención de evidencias de validez convergente-discriminante, las correlaciones entre las escalas primarias y secundarias del ASI-6 y las puntuaciones en la Impresión Clínica Global de Gravedad fueron bajas, oscilando entre 0,01 y 0,26. Asimismo, ocho de las quince escalas del ASI-6 lograron diferenciar entre controles y pacientes inestables. La versión española del ASI-6 presenta propiedades psicométricas que pueden ser consideradas aceptables, aunque sería necesario llevar a cabo nuevos estudios que continúen examinando su calidad métrica en muestras independientes de pacientes.AsturiasColegio Oficial de Psicólogos de Asturias; Calle Ildefonso Sánchez del Río, 4-1 B; 33003 Oviedo; Tel. +34985285778; Fax +34985281374;Universidad de Oviedo. Facultad de Psicología; Plaza Feijoo, s. n.; 33003 Oviedo; Tel. +34985104146; Fax +34985104126;ES